Think of Verquvo as a “Niche” Med for Heart Failure
April 2021
Reps will tout Verquvo (vericiguat) as a new once-daily add-on for worsening heart failure with reduced ejection fraction (HFrEF).
Verquvo is the first “soluble guanylate cyclase stimulator” for HFrEF. It relaxes blood vessels through the nitric oxide pathway.
Most evidence is in patients already on triple therapy...an ACEI, ARB, or Entresto (sacubitril/valsartan), beta-blocker (carvedilol, etc), AND aldosterone antagonist (spironolactone, etc).
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote